Brief: Osteopore Partners With Cytomed To Advance MSC-Powered Regeneration
17/10/2024 02:08
Oct 17 (Reuters) - Osteopore Ltd OSX.AX :
* OSTEOPORE PARTNERS WITH CYTOMED TO ADVANCE MSC-POWERED
REGENERATION
* COLLABORATION TO COMBINE CYTOMED'S MESENCHYMAL STEM CELLS
WITH
CO'S BIORESORBABLE SCAFFOLDS
Further company coverage: OSX.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CytoMed Therapeutics
See all newsBrief: Cytomed Therapeutics Limited Announces Receipt Of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Brief: Cytomed Therapeutics Refutes "Misleading" Claims & Reaffirms Clinical Progress
Brief: Cytomed Therapeutics Completes Acquisition Of T Cell Technology From Uk To Treat Cancers In China And India
Brief: CytoMed Therapeutics To Start Dose Level 2 In Angelica Trial Q3 2025
Brief: Cytomed Therapeutics Ltd Files For Mixed Shelf Of Up To $50 Million